Abstract
Tumor necrosis factor-induced protein-8 (TIPE) is highly expressed in colorectal cancer (CRC). Decoy receptor 3 (DcR3) is a soluble secreted protein that can antagonize Fas ligand (FasL)-induced apoptosis and promote tumorigenesis. It remains unclear whether TIPE can regulate DcR3 expression. In this study, we examined this question by analyzing the relationship between these factors in CRC. Bioinformatics and tissue microarrays were used to determine the expression of TIPE and DcR3 and their correlation in CRC. The expression of TIPE and DcR3 in colon cancer cells was detected. Plasma samples were collected from CRC patients, and DcR3 secretion was measured. Then, dual-luciferase reporter gene analysis was performed to assess the interaction between TIPE and DcR3. We exogenously altered TIPE expression and analyzed its function and influence on DcR3 secretion. Lipopolysaccharide (LPS) was used to stimulate TIPE-overexpressing HCT116 cells, and alterations in signaling pathways were detected. Additionally, inhibitors were used to confirm molecular mechanisms. We found that TIPE and DcR3 were highly expressed in CRC patients and that their expression levels were positively correlated. DcR3 was highly expressed in the plasma of cancer patients. We confirmed that TIPE and DcR3 were highly expressed in HCT116 cells. TIPE overexpression enhanced the transcriptional activity of the DcR3 promoter. TIPE activated the PI3K/AKT signaling pathway to regulate the expression of DcR3, thereby promoting cell proliferation and migration and inhibiting apoptosis. In summary, TIPE and DcR3 are highly expressed in CRC, and both proteins are associated with poor prognosis. TIPE regulates DcR3 expression by activating the PI3K/AKT signaling pathway in CRC, thus promoting cell proliferation and migration and inhibiting apoptosis. These findings may have clinical significance and promise for applications in the treatment or prognostication of CRC.
Highlights
Colorectal cancer (CRC) kills nearly 2 million people each year, making it the fourth deadliest cancer worldwide behind lung, liver and stomach cancers [1]
To investigate the role of Tumor necrosis factor-induced protein-8 (TIPE) and Decoy receptor 3 (DcR3) in human colorectal cancer (CRC), we first analyzed the available datasets of CRC patients in the Cancer Genome Atlas (TCGA) database, and the differential expression of TIPE and DcR3 in CRC tissues and adjacent tissues was randomly validated with Gene Expression Profiling Interactive Analysis (GEPIA; http://gepia.cancer-pku.cn/index.html)
The bioinformatics results showed that TIPE and DcR3 expression was significantly increased in CRC tissues compared to adjacent tissues at the mRNA level, and the difference in DcR3 expression was significant (Figures 1A, B)
Summary
Colorectal cancer (CRC) kills nearly 2 million people each year, making it the fourth deadliest cancer worldwide behind lung, liver and stomach cancers [1]. According to The Global Cancer Observatory (GLOBOCAN) 2018 data (http://gco.iarc.fr), CRC is currently the most common malignant tumor in China, ranking first in prevalence and second in incidence. Chemotherapy, radiotherapy and molecular targeted therapy are the most commonly used treatments for CRC, but the survival rate remains low [2]. Patients with advanced CRC who receive radiation therapy and chemotherapy experience serious adverse reactions. The development of new, effective treatment strategies is urgently needed. Researchers are devoted to elucidating the molecular mechanism of the occurrence and development of CRC [3]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.